Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd (TAK)

Takeda Pharmaceutical Co. Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Takeda Pharmaceutical Co. Ltd 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku Tokyo M0 103-8668 JPN

P: 813-3278-2306 F: 604-757-7180

Description:

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

Key Statistics

Overview:

Market Capitalization, $K 63,059,740
Shares Outstanding, K 3,117,140
Annual Sales, $ 18,875 M
Annual Net Income, $ 982,130 K
Last Quarter Sales, $ 7,543 M
Last Quarter Net Income, $ 500,750 K
60-Month Beta 0.76
% of Institutional Shareholders 4.58%
Float, K 3,117,140
% Float 100.00%

Growth:

1-Year Return 16.00%
3-Year Return 0.52%
5-Year Return -3.51%
5-Year Revenue Growth 11.58%
5-Year Earnings Growth -13.56%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 48.00 on 02/01/19
Next Earnings Date 02/07/20
Earnings Per Share ttm 2.03
EPS Growth vs. Prev Qtr 5.36%
EPS Growth vs. Prev Year -3.28%
Annual Dividend Rate, $ 0.60
Annual Dividend Yield 2.96%
Most Recent Dividend 0.300 on 09/27/19
Next Ex-Dividends Date 09/27/19
Dividend Payable Date 12/12/19
Dividend Payout Ratio 9.84

TAK Ratios

Ratio
Price/Earnings ttm 10.01
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) 12.52
Return-on-Assets (Before Tax) 4.61
Profit Margin % 5.20
Net Margin % N/A
Debt/Equity 1.05
Price/Sales 3.36
Price/Cash Flow 9.24
Price/Book 1.40
Book Value/Share 14.53
Interest Coverage 2.14

TAK Dividends

Date Value
09/27/19 $0.3000
09/27/18 $0.2880
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar